Prostate Cancer Treatment

ENZALUTAMIDE (BDENZA) Tablet

$612.00 – $630.00

Enzalutamide has a manageable safety profile, with common side effects including fatigue, hypertension, diarrhea, and musculoskeletal events. Patients should be closely monitored for adverse reactions, and dose adjustments may be necessary to manage side effects effectively

Strength	Choose an option40mg80mg160mg
	Clear

Quantity

ENZALUTAMIDE (BDENZA) Tablet quantity

Add to cart

Sku:

N/A

Description

Enzalutamide (BDenza) 40/80/160mg Capsule Tablet is an advanced medication utilized in the treatment of metastatic castration-resistant prostate cancer (mCRPC), a type of prostate cancer that no longer responds to hormonal therapies. This medication contains enzalutamide as its active ingredient, a potent androgen receptor inhibitor that effectively suppresses the growth and spread of prostate cancer cells.

Key Features:

• Androgen Receptor Inhibitor: Enzalutamide acts as a potent inhibitor of the androgen receptor, blocking the binding of androgens (such as testosterone) to the receptor and inhibiting downstream signaling pathways involved in prostate cancer growth and progression. By targeting the androgen receptor, enzalutamide effectively suppresses tumor growth and metastasis in mCRPC.
• Treatment of Metastatic CRPC: Enzalutamide (BDenza) 40/80mg Capsule Tablet is specifically indicated for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have previously received docetaxel chemotherapy. It offers a targeted treatment option for patients with advanced prostate cancer that has progressed despite hormonal therapy.
• Oral Administration: Enzalutamide (BDenza) 40/80/160mg Capsule Tablet is administered orally, typically once daily, with or without food. The convenient dosing regimen enhances patient compliance and adherence to treatment.
• Dose Flexibility: Enzalutamide (BDenza) 40/80/160mg Capsule Tablet is available in two strengths, 40mg and 80mg, allowing for individualized dosing based on patient response and tolerability. This flexibility enables healthcare providers to tailor treatment to meet the specific needs of each patient.
• Efficacy: Clinical trials have demonstrated the efficacy of enzalutamide in prolonging progression-free survival, overall survival, and improving quality of life in patients with metastatic CRPC. It has shown superiority over placebo and other conventional treatments, offering new hope for patients with advanced prostate cancer.
• Safety Profile: Enzalutamide has a manageable safety profile, with common side effects including fatigue, hypertension, diarrhea, and musculoskeletal events. Patients should be closely monitored for adverse reactions, and dose adjustments may be necessary to manage side effects effectively.
• Patient Education: Patients prescribed Enzalutamide (BDenza) 40/80/160mg Capsule Tablet should receive comprehensive education regarding proper medication administration, potential side effects, and the importance of adherence to treatment. This empowers patients to actively participate in their healthcare management and optimize therapeutic outcomes.
• Consultation with Healthcare Provider: Treatment with Enzalutamide (BDenza) 40/80mg Capsule Tablet should be initiated and monitored by a qualified oncologist or healthcare provider experienced in the management of prostate cancer. Close monitoring and regular follow-up are essential to ensure optimal therapeutic response and patient safety.
• Access and Affordability: Efforts should be made to ensure equitable access to Enzalutamide (BDenza) 40/80/160mg Capsule Tablet for eligible patients, including exploring financial assistance programs and insurance coverage options to mitigate any financial barriers to treatment. Access to innovative prostate cancer medications is crucial to improving patient outcomes and quality of life.

Additional information